0001179110-17-014597.txt : 20171124 0001179110-17-014597.hdr.sgml : 20171124 20171124175442 ACCESSION NUMBER: 0001179110-17-014597 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171121 FILED AS OF DATE: 20171124 DATE AS OF CHANGE: 20171124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dorsch Marion CENTRAL INDEX KEY: 0001690460 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 171221733 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 edgar.xml FORM 4/A - X0306 4/A 2017-11-21 2017-11-22 0 0001597264 Blueprint Medicines Corp BPMC 0001690460 Dorsch Marion C/O BLUEPRINT MEDICINES CORPORATION 38 SIDNEY STREET, SUITE 200 CAMBRIDGE MA 02139 0 1 0 0 Chief Scientific Officer Common Stock 2017-11-21 4 S 0 500 64.44 D 0 D The sales reported on this Form 4/A were effected pursuant to a trading plan adopted on June 22, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. This amendment is being filed solely to correct the fact that the original filing inadvertently stated that these securities were acquired, rather than disposed of. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.42 to $64.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges. /s/ Christopher Frankenfield, Attorney-in-Fact 2017-11-24